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Wingless/Int (Wnt) signaling pathways are signal transductionmechanisms that have been widely studied in the field of embryogen-
esis. Recent work has established a critical role for these pathways in brain development, especially of midbrain dopaminergic neu-
rones. However, the fundamental importance of Wnt signaling for the normal function of mature neurones in the adult central
nervous system has also lately been demonstrated by an increasing number of studies. Parkinson’s disease (PD) is the second most
prevalent neurodegenerative disease worldwide and is currently incurable. This debilitating disease is characterized by the progres-
sive loss of a subset ofmidbraindopaminergic neurones in the substantia nigra leading to typical extrapyramidalmotor symptoms. The
aetiology of PD is poorly understood but work performed over the last two decades has identified a growing number of genetic defects
thatunderlie this condition.Herewereviewagrowingbodyofdataconnectinggenes implicated inPD—mostnotably thePARKgenes—
with Wnt signaling. These observations provide clues to the normal function of these proteins in healthy neurones and suggest that
deregulated Wnt signaling might be a frequent pathomechanism leading to PD. These observations have implications for the patho-
genesis and treatment of neurodegenerative diseases in general.
Keywords: Wnt signaling, neurodegeneration, Parkinson’s disease, genetics of Parkinson’s disease, LRRK2, treatment
Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative
disease first described in 1817 as a ‘shaking palsy’ (Parkinson,
2002). Individuals with PD typically present with motor
dysfunction—the four cardinal symptoms being resting tremor,
bradykinesia, rigidity, and postural instability—although addition-
al non-motor symptoms such as dementia and depression are very
common (Dauer and Przedborski, 2003; Gasser, 2009). Patholog-
ically, post-mortem brains from PD patients display two hallmarks.
First, the presence of Lewy bodies—proteinaceous deposits rich in
a-synuclein protein—and second, the loss of dopaminergic (dopa-
mine producing) neurones of the substantia nigra pars compacta
(Dauer and Przedborski, 2003; Gasser, 2009). However, despite
nearly 200 years of study PD is still incurable, with the molecular
events underlying the aetiology and progression of the disease
remaining stubbornly hidden. Treatments for PD remain focused
on alleviating symptoms and the most common therapeutic strat-
egy, pharmacological replacement of lost dopamine, was first
described over 40 years ago (Cotzias et al., 1969). Since the
major risk factor for PD is age, the increased life expectancies
observed across much of the world mean that PD will place a
large burden on healthcare systems in years to come. As such,
the development of novel treatments for PD—most importantly
drugs that cure or at least arrest disease progression—is of impera-
tive clinical need. Thus an understanding of the molecular mechan-
isms underlying PD is urgently required.
In this article we summarize recent data from the study of genes
linked to PD that suggest a central importance of Wingless/Int
(Wnt) signaling pathways for the normal function of dopaminergic
neurones. These hereditary clues indicate that perturbation of
these cell signaling cascades might represent a key event in the
early pathogenesis of PD. Deregulation of Wnt signaling has the po-
tential to explain many of the commonly observed features of neu-
rodegeneration, while the sheer number of genes implicated in PD
that are also involved in Wnt signaling is compelling. In light of the
vital requirement for improved PD treatments and the therapeutic
potential of targeting signal transduction cascades, these connec-
tions between PD and Wnt signaling make a persuasive and timely
case for research into the role of Wnt pathways in the adult brain,
both in health and disease.
The canonical Wnt pathway
Wnt signaling pathways are a group of highly conserved cell sig-
naling cascades with a well-established importance to animal devel-
opment and cancer biology (Maiese et al.,2008; Freese et al.,2010).
There are generally considered to be three major branches of Wnt
signaling: the so-called canonical (or Wnt/b-catenin), planar cell
polarity (PCP), and Wnt/calcium (Wnt/Ca2+) cascades. This
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article will focus on the canonical pathway since the majority of re-
search reviewed focuses on this signaling cascade. Nonetheless, it
should be stressed that roles for the PCP and Wnt/Ca2+pathways in
the pathogenesis of PD cannot be excluded.
The term Wnt describes the secreted ligand proteins that bind to
the extracellular domains of frizzled (FZD) receptors on target cells.
Wnt ligands are usually glycosylated and are relatively large for
secreted morphogens, suggesting that the sites of secretion and
action tend to be relatively close (i.e. Wnt ligands are predominant-
ly autocrine and paracrine, rather than endocrine). In humans there
are 19 genes encoding Wnt ligands and 10 genes encoding FZD
receptors (Wnt home page: http://www.stanford.edu/group/
nusselab/cgi-bin/wnt/). Further signaling complexity is conferred
by membrane co-receptors. In the case of the canonical Wnt
pathway, these receptors are low density lipoprotein receptor-
related proteins 5 and 6 (LRP5/6). The binding of Wnt ligands to
the combination of FZD and LRP5/6 proteins allows the extracellu-
lar signal to be relayed across the plasma membrane, leading to the
activation of intracellular signaling.
The classical output of the canonical Wnt pathway is the activa-
tion and nuclear recruitment of b-catenin (hence the alternative
name, Wnt/b-catenin signaling). The canonical pathway is unusual
as several events take place in the absence of a stimulus. In the
basal state, b-catenin is sequestered into an inhibitory cytosolic
complex known as the b-catenin destruction complex. Within this
complex b-catenin is phosphorylated by glycogen synthase kinase
3b (GSK3b), resulting in the targeting of b-catenin for proteosomal
degradation. Thus, in the absence of stimulation by Wnt ligand,
b-catenin is continually degraded. The activation of FZD receptors
causes the recruitment of dishevelled (DVL) proteins to the plasma
membrane, where DVLs are thought to associate with the intracellu-
lar surface of FZD receptors. Through additional interaction with com-
ponents of theb-catenin destruction complex, DVL proteins mediate
the relocalization of the b-catenin destruction complex to juxta-
membrane sites. The resultant formation of large membrane-
spanning complexes, containing extracellular ligand, transmem-
brane receptors, and a multitude of intracellular proteins, has
been termed a Wnt ‘signalosome’. Wnt signalosomes have one
basic purpose: the inhibition of b-catenin phosphorylation, allow-
ingb-catenin to become resistant to proteosomal degradation. As a
result, b-catenin can accumulate and spread throughout the cell.
Most importantly, b-catenin binds to a number of transcription
factors, and via transcriptional co-factor activity, modulates the ex-
pression of downstream genes. The best described targets of
b-catenin are T-cell transcription factor/lymphoid enhancer binding
factor family transcription factors, although other unrelated tran-
scription factors can also be regulated byb-catenin. The mechanism
by which b-catenin phosphorylation is repressed in signalosomes is
not clear, but appears to involve two processes. Firstly, the intracel-
lular C-termini of LRP5/6 co-receptors are able to compete with
b-catenin as phosphorylation substrates for GSK3b. Secondly, signa-
losome formation triggers internalization of the entire complex from
the plasma membrane into the endosomal system. This complex
continues to signal from the cytosolic face of intracellular mem-
branes until it is eventually sequestered into multi-vesicular
bodies. It is believed that this removes the canonical Wnt signaling
pool of GSK3b from the cytosol, which in turn protects newly
synthesized b-catenin from proteosomal targeting (Dobrowolski
and De Robertis, 2012) (Figure 1).
The importance of Wnt signaling to higher brain function
A key role for Wnt cascades during embryogenesis is well estab-
lished. It is thus unsurprising that Wnt signaling has been impli-
cated as a master regulator of neurogenesis including adult
neurogenesis (Zhang et al., 2011). Nonetheless, recent advances
indicate a critical requirement for these signal transduction
mechanisms in regulating the function of mature neurones.
These roles of Wnt signaling range from supporting pre- and post-
synaptic functioning to transcriptional regulation and have been
reviewed in detail by others (Inestrosa and Arenas, 2010;
Maguschak and Ressler, 2012; Wisniewska, 2013). Predictably
therefore, behavioural and cognitive defects have been reported
in adult mice with genetically modified Wnt signaling components
(Maguschak and Ressler, 2012; Wisniewska, 2013). Importantly,
Wnt signaling appears to be vital for both neuronal survival and
regulation of higher brain function in adults. Therefore deregula-
tion of these cascades is suggested to contribute to the pathogen-
esis of neurological and psychiatric diseases.
Wnt pathways appear to have particular importance in specific
brainregions. Forexample, the canonicalpathway has beenreported
to upregulate expression of the Ca2+ channel Cav3.1 in the thal-
amus, leading to enhanced T-type Ca2+ currents (Wisniewska
et al., 2010). Roles in adult neurogenesis also suggest an acute re-
quirement for Wnt signaling in proliferative regions such as the
subventricular zone (Lie et al., 2005). However, an abundance of
data suggests a critical requirement of Wnt signaling for the
normal function of midbrain dopaminergic neurones. The number
of genes encoding Wnt signaling proteins shown to be required for
the normal development of this brain region in studies of transgenic
mice models is remarkable (Table 1). This vast amount of data is
reviewed comprehensively elsewhere (Castelo-Branco and Arenas,
2006; Alves dos Santos and Smidt, 2011). Importantly, evidence of
perturbed Wnt signaling has also been reported in adults with dis-
eases associated with dopaminergic neuronal dysfunction. For
example, genes encoding a number of Wnt components have been
linked to schizophrenia (De Ferrari and Moon, 2006; Mao et al.,
2009; Wisniewska, 2013), while, as we outline below, hereditary
forms of PD are also clearly connected to deregulated Wnt signaling
(Berwick and Harvey, 2012b).
Thus Wnt signaling pathways appear to be important regulators
of neuronal function throughout life, and deregulation is likely to
play a major role in the pathogenesis of neurological diseases.
Sufficient data exist to suggest a particular requirement for well-
regulated Wnt signaling within the dopaminergic neurones lost in
PD. As we argue below, this makesthe growingevidence of aconnec-
tion between Wnt signaling and familial forms of PD particularly in-
triguing.
Familial PD genes and Wnt signaling
In the vast majority of cases PD is an idiopathic condition.
Although a number of environmental risk factors have been identi-
fied, such as exposure to certain pesticides, the major determining
factor is age. Nonetheless, our understanding of PD has changed
dramatically in recent years with the discovery of gene mutations
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that can cause the disease. Genes identified at genetic loci previ-
ously identified in linkage studies of individuals with familial PD
are often referred to as PARK genes. Nonetheless, additional
genes and loci have been identified in studies of individual families
andgenome-wide associationstudies. Below, wesummarizethe evi-
dence linking a striking number of these genes to canonical Wnt sig-
naling (summarized in Table2) and argue a persuasive case for a key
role of deregulated Wnt cascades in the pathogenesis of PD.
LRRK2
Mutations in LRRK2 are found at the PARK8 locus, and have been
identified as a cause of a familial Parkinson’s. LRRK2 encodes a
member of the Roco family of proteins called leucine-rich repeat
kinase 2 (LRRK2) (Paisa´n-Ruı´z et al., 2004; Zimprich et al., 2004).
Intriguingly, although beyond the scope of this review, LRRK2 has
also been associated with cancer, leprosy, and Crohn’s disease
(Hassin-Baer et al., 2009; Van Limbergen et al., 2009; Zhang et al.,
2009). LRRK2mutations contributeto1%–5%of PD casesworldwide,
which represents the greatest contribution from any known cause, en-
vironmental or genetic (Kumari and Tan,2009). It has been suggested
that the study of LRRK2 function may be especially informative for PD,
since patients with LRRK2 mutations display clinical symptoms that
are indistinguishable from idiopathic PD, and post-mortem brain
pathologies are also largely identical (Zimprich et al., 2004). In add-
ition to these classical PD traits, post-mortem pathology has
revealed an increased tendency of PD patients with LRRK2 muta-
tions to display aggregates of tau protein (Zimprich et al., 2004;
Khan et al., 2005; Rajput et al., 2006; Ujiie et al., 2012). Tau
Figure 1 Potential sites of canonical Wnt signaling deregulation in PD. As outlined in the main text, six proteins—GSK3b, LRRK2, Nurr1, Parkin,
VPS35, and WNT3—have been linked to canonical Wnt signaling and genetic risk of PD. The sites where these proteins affect the canonical pathway
are represented graphically. The diagram is divided into three sections; from left-to-right these are (i) basal canonical Wnt signaling, (ii) activated
Wnt signaling, and (iii) Wnt secretion. (i) In the basal state, b-catenin, the main effector of the canonical Wnt pathway, is repressed by GSK3b,
LRRK2, and Parkin. GSK3b phosphorylatesb-catenin, triggering the ubiquitination (Ub) of this protein by Parkin, leading to the proteosomal deg-
radation ofb-catenin. (ii) Upon binding of Wnt ligand such as WNT3, LRRK2,b-catenin, GSK3b, and associated proteins are recruited to membrane
receptor complexes. The phosphorylation ofb-catenin by GSK3b is repressed, stabilizingb-catenin and allowing this protein to enter the nucleus.
Nuclearb-catenin binds and transactivates target transcription factors including Nurr1, driving the expression of downstream genes. In both basal
and activated conditions LRRK2 functions as a scaffolding protein. (iii) Wnt ligand secretion is mediated by Wntless (WTL), which transports Wnt
ligands from the trans-Golgi network to the plasma membrane where Wnts are released. This process is dependent on the recycling of Wntless back
from the plasma membrane, via early endosomes to the trans-Golgi network. This last step is mediated by the retromer complex, of which VPS35 is
an essential component. Loss of VPS35 function leads to an accumulation of Wntless in the endosomal system, and decreased secretion of Wnt
ligands.
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pathology is usually considered a feature of Alzheimer’s disease
(AD) (Inestrosa et al., 2012). These observations have led to the
suggestion that LRRK2 might function upstream of signaling path-
ways contributing to the pathogenesis of multiple forms of neuro-
degeneration (Taymans and Cookson, 2010).
LRRK2 is a complex 2527 amino acid protein, containing both
kinase and GTPase activities as well as a number of protein–
protein interaction domains. LRRK2 GTPase activity is conferred
by the presence of adjacent Roc (Ras of complex proteins) and
COR (C-terminal of Roc) domains, which together can be considered
a single RocCOR tandem domain since Roc and COR domains are
always expressed together in nature (Marı´n et al., 2008). Curiously,
extensive research has failed to identify a reproducible kinase sub-
strate for LRRK2, although a very wide range of interacting proteins
have been found, suggesting that LRRK2 may function primarily as
a scaffolding protein (Berwick and Harvey, 2011; Lewis and
Manzoni, 2012). Both the kinase and GTPase activities of LRRK2 do
appear important for function however. Although amino acid varia-
tions have been identified throughout the LRRK2 protein sequence,
the only changes proven to segregate with PD come from mutations
in exons encoding these enzymatic activities. At the level of protein
function, LRRK2 has been linked to a number of cellular processes,
including autophagy, vesicle trafficking, and microtubule dynamics.
However, the precise roles of this protein remain unclear.
Via interactions with a number of established Wnt signaling com-
ponents, LRRK2 has been strongly implicated as a key
scaffold protein in the canonical pathway. Initial work using yeast
two-hybrid, co-immunoprecipitation, and confocal microscopy
reported a direct interaction between LRRK2 and all three mamma-
lian DVL proteins (Sancho et al., 2009). In light of the central role of
DVL proteins in all major branches of Wnt signaling, this observation
could be of great importance. The interaction surfaces were mapped
to the LRRK2 RocCOR tandem domain and the dishevelled–Egl10–
pleckstrin domain of DVL1-3, and perhaps predictably, LRRK2muta-
tions within the RocCOR domain were found to modulate interaction
strength (Sancho et al., 2009). Functional follow-up studies used
TOPflash assays (Veeman et al., 2003) to quantify b-catenin tran-
scriptional activity (i.e. canonical Wnt signaling). Co-transfection of
LRRK2 protein with DVL1-3 increased DVL-driven canonical Wnt ac-
tivity (Berwick and Harvey, 2012a). Importantly, the LRRK2 muta-
tions R1441C, Y1699C, and G2019S, which reside within the Roc,
COR, and kinase domains, respectively, were all found to weaken
this effect. Furthermore, artificial mutations to the Roc and kinase
domain that rendered LRRK2 GTPase- or kinase-dead were also
found to be inhibitory, as was the pharmacological inhibition of
LRRK2 kinase activity. Clearly, the implications of mutations
throughout LRRK2 all inhibiting canonical Wnt signaling are poten-
tially of vast significance.
The capacity for LRRK2 to enhance DVL1-driven Wnt signaling
increased further by targeting LRRK2 to membranes. In agreement
with this, LRRK2was discovered to bind directly to the intracellular
domain of the LRP6membrane receptor, while treatment of HEK293
cells with recombinant Wnt3a increased the amount of endogen-
ous LRRK2 protein present in membrane fractions. These observa-
tions are consistent with the Wnt signalosome hypothesis and
suggest that LRRK2 affects canonical pathway activity at cellular
membranes (Berwick and Harvey,2012a). Similar to the interaction
with DVL proteins, the binding of LRRK2 to LRP6 was found to
require the LRRK2 RocCOR tandem domain (Berwick and Harvey,
2012a). Moreover, quantitative yeast two-hybrid assays revealed
the strength of the LRRK2–LRP6 interaction to be weakened by
the R1441C, R1441G, and Y1699C LRRK2 mutations. Taken to-
gether, these data suggest a model where in response to Wnt
ligand, LRRK2 is recruited to cellular membranes where, via inter-
action with DVL proteins and LRP6, this protein plays an important
role in signalosome formation.
Table 1 Genes linked to both Wnt signaling and midbrain dopaminergic development
Protein Description Key reference
WNT1 Canonical Wnt ligand required for dopaminergic development in mouse. Castelo-Branco et al. (2003)
WNT3A Canonical Wnt ligand required for dopaminergic development in mouse. Castelo-Branco et al. (2003)
WNT5A PCP pathway ligand required for dopaminergic development in mouse. Castelo-Branco et al. (2003)
SRFP1 Secreted Wnt modulator. Compound knockout with SRFP2 phenocopies WNT5A knockout. Kele et al. (2012)
SRFP2 Secreted Wnt modulator. Compound knockout with SRFP1 phenocopies WNT5A knockout. Kele et al. (2012)
DKK1 Secreted Wnt inhibitor. Required for midbrain differentiation. Ribeiro et al. (2011)
FZD3 FZD receptor. Simultaneous knockout with FZD6 causes defective midbrain morphogenesis. Stuebner et al. (2010)
FZD6 FZD receptor. Simultaneous knockout with FZD3 causes defective midbrain morphogenesis. Stuebner et al. (2010)
LRP6 Wnt co-receptor. LRP6 knockout mice display delayed dopaminergic differentiation. Castelo-Branco et al. (2010)
Wntless Required for Wnt ligand secretion. Knockout mice show severe mid- and hindbrain abnormalities.a Carpenter et al. (2010)
b-catenin Effector of canonical pathway. Knockout causes mid/hindbrain deformation.a Brault et al. (2001)
Nurr1 b-catenin-regulated transcription factor. Required for dopaminergic development in mouse. Zetterstro¨m et al. (1997)
aKnockout limited to Wnt1-expressing cells via Wnt1-CRE-driven recombination.
Table 2 Genes linked to both Wnt signaling and PD
Protein Description Key reference
LRRK2 Product of PARK8. Binds various canonical Wnt proteins and modulates pathway activity. Berwick and Harvey (2012a)
Parkin Product of PARK2. Represses b-catenin. Rawal et al. (2009)
VPS35 Product of PARK17. Required for Wnt secretion. Deng et al. (2013)
Nurr1 b-catenin effector. Loss of Nurr1 associated with PD pathology and motor dysfunction in mice. Kitagawa et al. (2007)
GSK3b Central canonical Wnt protein. Polymorphisms influence PD risk. Kwok et al. (2005)
WNT3 Wnt ligand. Possible PD risk locus in Ashkenazi Jewish populations. Liu et al. (2011)
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Surprisingly, siRNA-mediated knockdown of LRRK2 was also
found to enhance canonical Wnt signaling (Berwick and Harvey,
2012a). In agreement with this, murine embryonic fibroblasts
derived from LRRK2 knockout mice also display enhanced canonic-
al Wnt activity compared with wild-type controls (unpublished
data). Importantly, the effect of knocking down LRRK2 expression
was observed under Wnt3a- and DVL1-stimulated conditions but
also basally, suggesting an inhibitory role for LRRK2 in the
b-catenin destruction complex. Consistent with this idea,
co-immunoprecipitation of endogenous LRRK2 from mouse brain
revealed LRRK2 to exist in complex with multiple components of
the b-catenin destruction complex, including Axin1, GSK3b, and
b-catenin (Berwick and Harvey, 2012a). It should be noted that
an interaction between LRRK2 and GSK3b has been reported previ-
ously in Drosophila (Lin et al., 2010). Intriguingly, interaction
strength was reported to be enhanced by the G2019S LRRK2muta-
tion (Lin et al., 2010). Thus, not only does LRRK2 interact with nu-
merous components of the canonical pathway, but the strength of
interaction with at least three of these is affected by PD-causing
LRRK2 mutations.
Taken together, these data suggest a central role for LRRK2 in ca-
nonical Wnt signaling. Under basal conditions, LRRK2 forms part of
the cytosolic b-catenin destruction complex. Loss of LRRK2 com-
promises this role, leading to disruption of the complex and
pathway activation. Following stimulation with Wnt ligand, LRRK2
is recruited to membranes. Here, via interaction with DVL proteins,
the b-catenin destruction complex and LRP6, LRRK2 assists in the
formation of Wnt signalosomes, enhancing the activity of the ca-
nonical Wnt pathway. Familial LRRK2 mutations decrease the
ability of LRRK2 to enhance Wnt signaling activity.
Parkin
The E3 ubiquitin ligase Parkin is encoded by the PARK2 gene. In
contrast to LRRK2, PARK2 mutations represent a relatively rare
cause of PD, are inherited in an autosomal recessive manner, and
are considered loss-of-function mutations (Gasser, 2009).
Patients display an atypical form of PD, with early onset of motor
symptoms and a brain pathology that is largely restricted to loss
of dopaminergic neurones (Gasser,2009). PD caused by mutations
in PARK2 has been suggested to have much in common with other
early onset autosomal recessive forms of parkinsonism caused by
mutations in PINK1/PARK6 orDJ-1/PARK7. Perhaps unsurprisingly,
these autosomal recessive PD genes appear to function in a
common process, namely the regulation of mitophagy (autophagy
of mitochondria), and also interact genetically in animal models
(Dodson and Guo, 2007). However, the control of mitophagy is
only one aspect of Parkin function, as this protein contributes to
other cellular processes that when deregulated might contribute
to neurodegeneration.
Interestingly, Parkin has been reported to induce b-catenin ubi-
quitination and degradation, thereby repressing canonical Wnt ac-
tivity (Rawal et al., 2009). Concordantly, Parkin dysfunction
triggers an accumulation of b-catenin leading to up-regulation of
canonical Wnt signaling. Rawal et al. (2009) showed that
b-catenin protein levels, but not mRNA levels, were increased sig-
nificantly in the ventral midbrain of Parkin knockout mice compared
with wild-type controls, but intriguingly, not in other brain regions.
Since Wnt ligands are generally considered neuroprotective,
increased canonical Wnt signaling might seem a counter-intuitive
pathomechanism for PD. However, elevated Wnt signaling
leading to attempted cell-cycle re-entry in postmitotic neurones
is detrimental and has been reported in both AD brains and AD
mouse models (Currais et al., 2009). Consistent with this, Parkin
knockout mice were found to display increased levels of cyclin E
(Rawal et al., 2009). As such, one physiological role of Parkin func-
tion might be to protect dopaminergic neurones from excessive ca-
nonical Wnt signaling, particularly in brain regions implicated in the
pathogenesis of PD (Rawal et al., 2009). These observations
support the idea that Wnt signaling needs to be regulated within
well-defined boundaries, and also add weight to the notion that
the canonical Wnt pathway is particularly important in midbrain
dopaminergic neurones.
VPS35
Vacuolar sorting protein35homologue (VPS35) is the product of
the VPS35/PARK17 gene, and was identified as a cause of auto-
somal dominant PD in 2011 (Vilarin˜o-Gu¨ell et al., 2011; Zimprich
et al., 2011). The overall contribution of VPS35 mutations to PD
is thought to be low (Deng et al., 2013). However, several lines of
evidence suggest that the study of VPS35 protein function will be
particularly informative. Firstly, similar to LRRK2, patients with
mutations in VPS35 display symptoms that are very similar to idio-
pathic PD, including late age of onset. Indeed,VPS35mutations are
reckoned to be the second major genetic cause of late onset PD
after LRRK2 (Deng et al., 2013). Secondly, VPS35 has been linked
previously to AD. For example, the levels of VPS35 protein are
decreased in post-mortem brains of AD patients (Small et al.,
2005), while mice lacking VPS35 show behavioural and pathologic-
al features consistent with this disorder (Wen et al., 2011). In this
regard, VPS35 is also similar to LRRK2, since ‘tau pathology’,
usually a post-mortem hallmark of AD, has been described in
patients (Zimprich et al., 2004; Khan et al., 2005; Rajput et al.,
2006; Ujiie et al., 2012) and animal models harbouring LRRK2
mutations (Li et al., 2009; Lin et al., 2010; Melrose et al., 2010).
Thus it is interesting to speculate that LRRK2and VPS35might func-
tion in a common pathway that is required for neuronal survival
across the brain, but is especially vital in brain regions damaged
in idiopathic PD.
VPS35 is well described as a key component of the retromer
complex, important for the sorting and retrograde transport of
membrane-localized proteins from endosomes to the trans-Golgi
network (Seaman, 2012). Intriguingly, VPS35 has been tied to
Wnt signaling in a number of studies. Initial work published in
2006 described a requirement of the retromer complex for Wnt sig-
naling during embryogenic patterning in the model organism
Caenorhabditis elegans (Coudreuse et al., 2006; Prasad and
Clark, 2006). Providing a mechanistic interpretation for these
observations, a number of groups subsequently reported that
loss of VPS35 function prevents the endosome-to-Golgi recycling
of Wntless, a protein essential for secretion of Wnt ligands
(Belenkaya et al., 2008; Franch-Marro et al., 2008; Port et al.,
2008; Kim et al., 2009). This interaction between VPS35 and
Wntless is particularly fascinating in the context of PD, as mice
lacking Wntless display profound developmental abnormalities
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of the midbrain (Carpenter et al., 2010). The only established
PD-causing mutation in the VPS35 gene encodes a D620N amino
acid substitution (Deng et al., 2013). We are unaware of any
studies investigating the effect of D620N on Wnt signaling.
Nonetheless, we speculate that this mutation might impair
VPS35 function causing a gradual accumulation of Wntless within
the endosomal pathway subsequently leading to decreased Wnt
secretion and loss of Wnt signaling activity in neighbouring neu-
rones. If this hypothesis is correct, both mutations in LRRK2 and
VPS35 would contribute to the pathogenesis of PD by decreasing
Wnt signaling activity.
Nurr1
The transcription factor nuclear receptor-related protein 1
(Nurr1), encoded by NR4A2, is a well-established key regulator of
dopaminergic neuronal development during embryogenesis, and
important for the expression of genes regulating dopaminergic
neurotransmission (Arenas, 2005; Jankovic et al., 2005). Even
though sequence variations within NR4A2 are not considered a
widespread genetic cause of PD (Nichols et al., 2004; Tan et al.,
2004), one mutation leading to decreased Nurr1 expression has
been identified in a PD patient (Sleiman et al., 2009), and decreased
Nurr1 expression has also been reported in midbrain dopaminergic
neurones from patients with idiopathic PD (Jankovic et al., 2005). In
addition, Nurr1 knockout in midbrain dopaminergic neurones of
adult mice results in neuronal degeneration and impaired motor
function (Kadkhodaei et al., 2009). Nurr1 has also been reported
to regulate the expression of a-synuclein, the major component of
Lewy bodies, and the identified NR4A2 mutation increases the ex-
pression of a-synuclein (Yang and Latchman, 2008). Therefore, im-
pairment of Nurr1 activity is likely to impact upon PD progression
partially via upregulation of a-synuclein expression. Importantly,
Nurr1 has been reported to interact with b-catenin on promoters
of Wnt and Nurr1 responsive target genes (Kitagawa et al., 2007).
In particular, b-catenin and Nurr1 were shown to transactivate the
KCNIP4 promoter (Kitagawa et al., 2007). The possibility that
Nurr1and Wnt signaling pathways are able co-activategenes import-
ant for neurodegeneration is a tantalizing prospect.
GSK3b
GSK3b is well established as a critical component of the canon-
ical Wnt signaling pathway (Maiese et al.,2008; Freese et al.,2010;
Hur and Zhou, 2010; Taelman et al., 2010; Kim et al., 2011). The
gene encoding this protein (GSK3B) has been implicated in PD
risk in two genetic studies (Kwok et al., 2005; Kalinderi et al.,
2011), although a third found no association (Wider et al., 2011).
Therefore, GSK3bmay only contribute to PD risk in certain popula-
tions. GSK3 was first identified as a kinase phosphorylating glyco-
gen synthase (Woodgett and Cohen, 1984). The two isoforms,
GSK3a and GSK3b, are ubiquitously expressed in mammalian
cells and are considered constitutive kinases, i.e. they are inhibited
by activation of upstream signaling pathways, but are active under
basal conditions (Hur and Zhou, 2010; Kaidanovich-Beilin and
Woodgett, 2011; Kim et al., 2011). As might be expected, GSK3a
and GSK3b display some redundancy of function. However,
isoform-specific functions are probable, and thus the ratio and ab-
solute expression levels of these proteins vary between cell types.
Indeed, a brain-specific GSK3b splice-form has been described,
which is believed to play a specific role in neuronal differentiation
(Mukai et al., 2002; Wood-Kaczmar et al., 2009; Castan˜o et al.,
2010).
GSK3b can be modulated by a surprisingly large number of up-
stream signaling pathways. In addition to the canonical Wnt
cascade, pathways affecting GSK3b activity include phosphatidyli-
nositol 3′ kinase, notch and hippo (Kaidanovich-Beilin and
Woodgett, 2011). The requirement of one protein to function in
so many pathways, while still retaining signal specificity, has led
to the suggestion that GSK3balmost certainly exists in distinct sub-
cellular pools. A number of neuronal GSK3b substrates have been
reported, including proteins implicated in synaptic plasticity, such
as dynamin-1 and gephyrin (Clayton et al., 2010; Tyagarajan et al.,
2011), and transcription factors, for example cAMP response
element binding protein (Grimes and Jope, 2001). However, it is
perhaps most interesting to note the number of microtubule
associated proteins (MAPs) that have been implicated as GSK3b
substrates. These include tau, collapsing response mediator
protein 2, and MAP1B (Mandelkow et al., 1992; Cole et al.,
2004; Trivedi et al., 2005). Thus, GSK3b appears to be a master
regulator of microtubule dynamics in neurones. Since GSK3b is a
LRRK2 interacting protein (Lin et al., 2010; Berwick and Harvey,
2012a) and LRRK2 was found in association with microtubules and
affects tau phosphorylation (Zimprich et al., 2004; Khan et al.,
2005; Biskup et al., 2006; Gloeckner et al., 2006; Rajput et al.,
2006; Gandhi et al., 2008; Gillardon 2009a, b; Sancho et al., 2009;
Dzamko et al., 2010; Lin et al., 2010; Kawakami et al., 2012; Kett
et al., 2012; Sheng et al., 2012; Ujiie et al., 2012), LRRK2 and
GSK3bmight form a Wnt ligand-regulated complex governing micro-
tubuledynamics inneurones.MAPT, the geneencodingtau, has also
been implicated as a major genetic determinant of PD (Golub et al.,
2009; Gonza´lez-Pe´rez et al., 2009; Satake et al., 2009;
Simo´n-Sa´nchez et al., 2009). Thus, these connections allow for the
possibility that mutations in LRRK2, GSK3B, or MAPT all result in
neurodegeneration via affecting microtubule function.
WNT3
TheWNT3gene encodes a conserved canonical Wnt ligand and is
located on chromosome 17 at 17q21, within a 1.8 Mb region of
linkage disequilibrium, centred on the MAPT gene (Caffrey and
Wade-Martins, 2007; Kalinderi et al., 2009; Liu et al., 2011). In
most human populations this genomic region forms a so-called
MAPTH1 haplotype, but among Caucasian populations an alterna-
tive MAPT H2 haplotype can be found (Caffrey and Wade-Martins,
2007; Kalinderi et al., 2009). There is little recombination within
this region due to the presence of a 900 kb inversion within the
centre of the MAPT H2 haplotype (Hardy et al., 2005). The MAPT
H1 haplotype has been repeatedly found to confer a greater risk
of PD in genome-wide association studies (Golub et al., 2009;
Gonza´lez-Pe´rez et al., 2009; Satake et al., 2009; Simo´n-Sa´nchez
et al., 2009). It has been suggested that variations within the
MAPT gene itself confer some or most of the MAPT H1 risk.
However, since the genes within the disequilibrium region all
co-segregate with MAPT, they are all potential risk factors.
Intriguingly, a detailed study of the MAPT H1 region in Ashkenazi
Jews found linkage with multiple regions within the region,
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including linkage toWNT3 (Liu et al.,2011). This research is at early
stages, and we note that no linkage to WNT3 could be found in
Russian PD patients (Filatova et al., 2011). Nonetheless, the possi-
bility that altered function of a Wnt ligand might affect PD risk is an
exciting possibility, and has clear implications for potential treat-
ments.
Additional connections between canonical Wnt signaling
and neurodegeneration
The presented genetic links between PD and Wnt signaling make
a powerful case for a role of canonical Wnt pathway deregulation in
the molecular aetiology of the disease. In addition, Wnt signaling is
deregulated in numerous animal models of toxin-induced PD
(L’Episcopo et al., 2011b; Dun et al., 2012; Gollamudi et al.,
2012), and in brains of PD patients (Cantuti-Castelvetri et al.,
2007). These observations speak for a potential causative role
and/or role in disease progression for perturbed Wnt signaling.
For example, Wnt signaling has been shown to be central to brain
inflammation and adult neurogenesis (Lie et al., 2005; Berwick
and Harvey, 2013; Marchetti and Pluchino, 2013). In rodent
models, reactive astrocytes and microglia have been reported to
protect dopaminergic neurones by activating canonical Wnt signal-
ing, and also by promoting neurogenesis of progenitor cells origin-
ating from the subventricular zone, via a mechanism partially
based on the interaction between inflammation and canonical
Wnt signaling (L’Episcopo et al., 2011a, b, 2012; Marchetti and
Pluchino, 2013).
Interestingly, deregulated Wnt signaling pathways are also sug-
gested pathomechanisms for a number of additional neurological
conditions, including AD, autism, and schizophrenia (see Table 3)
(De Ferrari and Moon, 2006; Inestrosa and Toledo, 2008; Berwick
and Harvey, 2012b; Kalkman, 2012). It is worth observing that
lithium, a pharmacological treatment for psychotic disorders, is a
well-established GSK3b inhibitor, i.e. this treatment might
involve canonical Wnt activation (Wisniewska,2013). The evidence
linking AD to Wnt signaling defects has resulted in a unifying hy-
pothesis for AD aetiology centred around deregulated Wnt cas-
cades (Inestrosa and Arenas, 2010). Importantly, post-mortem
brains from AD patients exhibit increased levels of GSK-3b, as
well as greater b-catenin phosphorylation, indicative of decreased
canonical Wnt activity (Caricasole et al., 2004; Inestrosa and
Arenas, 2010). Suggesting a plausible explanation for this,
Dickkopf-1 (Dkk1), a secreted protein that inhibits the canonical
pathway by binding to LRP6, was also found to be elevated in AD
brains (Caricasole et al., 2004; Inestrosa and Arenas, 2010).
Supporting this idea, Dkk1-neutralizing antibodies protect ex
vivomouse brain slices from synaptic loss caused by Ab oligomers
(Purro et al., 2012). Taken together, these data suggest a model
where Dkk1 inhibits Wnt signaling at the cell membrane, leading
to enhanced cellular GSK-3b activity and increased repression of
b-catenin. Since GSK-3b is considered the major kinase phos-
phorylating tau in vivo, this model also explains one of the major
pathological hallmarks of AD: hyperphosphorylated tau. Further
strengthening this hypothesis, GSK3B variants have been suggested
as a genetic risk factor for AD (Kwok et al., 2008). The connections
between LRRK2, GSK3b, and tau in PD are intriguing but clearly
provide a valid pathomechanism underlying AD. Furthermore, an
LRP6 variant conferring reduced Wnt signaling is associated with
AD in carriers of the ApoE4 risk variant in genome-wide association
studies (De Ferrari et al., 2007). Interestingly, LRP6 is not just a
direct interactor of LRRK2 (Berwick and Harvey, 2012a); VPS35 and
ATP13A2 (the product of the PARK9 gene) have also been reported
to bind the LRP6 intracellular domain (George et al., 2007; Usenovic
et al., 2012). These observations require follow-up studies, but if
correct, mean that a single canonical Wnt protein, itself a risk factor
for neurodegeneration, physically interacts with the products of no
less than three PARK genes.
Future research
It is clear that Wnt signaling pathways are of fundamental import-
ance to the function of adult neurones. This requirement appears
particularly acute for the dopaminergic neurones of the ventral
midbrain, and changes in established Wnt components appear to
influence PD risk. Vice versa, compelling genetic and functional
data indicate a number of PARK genes as important modulators
of the canonical Wnt pathway. In addition, Wnt signaling is un-
doubtedly central to processes that are critical for PD progression,
such as neuroinflammation, adult neurogenesis, microtubule sta-
bility, axonal function, and membrane trafficking (Inestrosa and
Arenas, 2010; Berwick and Harvey, 2011; Marchetti and
Pluchino, 2013). Thus, we contend that the evidence supporting
a key role for perturbed canonical Wnt signaling in the aetiology
of PD is both plausible and persuasive.
Despite this, a great deal of research remains to be carried out.
Most notably, there is no direct evidence that loss of canonical
Wnt signaling in the adult brain is sufficient to elicit PD.
Nonetheless, continuing genome-wide association studies may
provide additional links to Wnt signaling. Suggested associations
require further investigation. In particular, linkage of PD to the
WNT3 locus needs investigation in different populations. By con-
trast, GSK3B variants do appear to modulate PD risk in the
context of additional genetic cues, but probably not in all popula-
tions. Importantly, the effects of this genetic association need
detailed investigation in all signaling pathways involving GSK3b.
Further examinations of post-mortem PD brains might be useful,
and have already garnered evidence of altered canonical Wnt
Table 3 Genes linked to Wnt signaling and other neurological diseases
Protein Description Key reference
WNT2 Wnt ligand. Linked to autism. Marui et al. (2010)
FZD3 FZD receptor. Linked to schizophrenia in Asian populations. Katsu et al. (2003)
FZD9 FZD receptor. Linked to autism. Sanders et al. (2011)
LRP6 Wnt co-receptor. Modulates risk conferred by APOE isoforms in AD. De Ferrari et al. (2007)
DISC1 Schizophrenia risk gene. DISC1 activates canonical Wnt signaling via inhibition of GSK3b. Mao et al. (2009)
GSK3b (I) Central canonical Wnt component. Linked to genetic risk of AD. Kwok et al. (2008)
GSK3b (II) Central canonical Wnt component. Implicated in bipolar disorder as a target of lithium. Wisniewska (2013)
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signaling (Cantuti-Castelvetri et al.,2007). However, patient samples
invariably come from late-stage PD, where evidence of initial aeti-
ology will largely be masked by the more profound changes caused
by cell death. Instead, we anticipate more conclusive data from
animal models of early/preclinical stages of PD. Genes encoding ca-
nonical Wnt signaling proteins are required for the development of
midbrain dopaminergic neurones (Table 1), but the functions of
these genes in neurodegeneration are less clear. Therefore, the
use of inducible conditional knockout/knock-in rodent models,
or viral gene transduction to modify protein expression in adult
rodents, might be more informative (Wilkinson et al., 2011).
These animals could be tested for motor, cognitive, behavioural,
and electrophysiological defects, and tissue investigated for neu-
rodegenerative changes. Here, the investigator would encounter
the difficulties of recapitulating PD in an organism that rarely
lives beyond2 years of age, and displays little evidence of neurode-
generation under ordinary conditions. Nonetheless, we are confi-
dent that with the right experimental design this approach can be
fruitful. For example, conditional knockout mice could be treated
with low doses of toxins (i.e. 6-hydroxydopamine or 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine) to provide an additional ‘envir-
onmental’ stress triggering a more profound phenotype.
As a final observation, we should highlight the potential implica-
tions of a causal role for altered canonical Wnt signaling in PD aeti-
ology for the treatment of this condition. In particular, the
development of targeted methods for regulating Wnt signaling
might be considered as a strategy for new therapies in the future
(Inestrosa and Arenas, 2010). Even if such treatments fail to cure
the disease, one might at least expect enhanced Wnt signaling to
support adult neurogenesis and normal synaptic function. In add-
ition, modulation of inflammatory responses by Wnt signaling
would also be predicted to improve symptoms. It is also worth
noting that one therapeutic strategy currently under develop-
ment—implantation of dopaminergic neuronal precursors derived
from human stem cells—is crucially dependent on Wnt ligands for
programming and specification (Kriks et al., 2011).
In conclusion, evidence fora role ofderegulated canonical Wnt sig-
naling as an important cause of familial and idiopathic PD is accumu-
lating. Nonetheless, this hypothesis needs further investigation in
adult animal models. We stress that targeting Wnt cascades at differ-
ent points inthe signaling cascaderepresentsa promisingtherapeut-
ic approach for modulating PD progression. It is therefore crucial that
we acquire more knowledge of the specific pathways involved in the
pathogenesis of the disease. Key remaining questions include: What
is the exact role of PARK genes? And, which Wnt receptors might be
promising therapeutic targets for small molecules?
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